Register for our free email digests:
Latest From Organon USA Inc.
Government contends a price reduction is the only discount exception to the Anti-Kickback Statute; PhRMA says this interpretation puts companies at risk of criminal liability for other discount arrangements.
Court finds FDA erred in not giving the fixed-dose combo product Prepopik five years of market exclusivity since it had awarded the exclusivity to similarly situated single-entity drug products.
Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.
Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- Senior Management
- Guido Oelkers, CEO
- Contact Info
Phone: (91) 79 4000 6300
1 Ashoknagar Bungalows
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.